RecruitingNCT06043011

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Sponsor

iOMEDICO AG

Enrollment

2,950 participants

Start Date

Sep 27, 2023

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Waldenström's Macroglobulinemia (WM)

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Age ≥ 18 years
Confirmed diagnosis of the respective NHL
If patient is alive: signed written informed consent
For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.